Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases

Ocata Therapeutics, Inc. OCAT, a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150. "The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the leadership position we have established as pioneers in Regenerative Ophthalmology," said Paul K. Wotton, Ph.D., President and Chief Executive Officer. "In particular, this new patent provides coverage for the manufacture of all RPE products from any pluripotent source by defining the basic universal markers of RPE essential for therapeutic use. We have recently received patent protection for the manufacture of human RPE cell products from pluripotent stem cell sources, including manufacture of formulation forms for use as therapeutic agents as well as the use of these RPE formulations for treating degenerative ophthalmic diseases, such as dry age-related macular degeneration (dry AMD) and Stargardt's macular degeneration (SMD)."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!